EMB-01 for advanced stomach, bile, liver, and colon cancers
Treatments studied
Part of Cancer clinical trials.
This early-phase trial studies EMB-01 in people with advanced or metastatic gastrointestinal cancers to see how well it works and how safe it is. To join, your tumor’s DNA or protein pattern (especially EGFR or cMET) must match specific lab results, and you must have tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic gastric cancer, liver cancer (HCC), bile duct cancer (BTC), or colorectal cancer that has measurable spots
- You must have tried all standard treatments that usually help—or you can’t tolerate them, or none are available, or you chose not to take them
- You must be willing to sign the consent forms and complete required testing
- You need a tumor sample or a blood test for EGFR/cMET markers: for many people this is required to qualify
- Your body must be strong enough for treatment (adequate organ function) and you should be able to do daily activities at a low-to-mild level (ECOG 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether a c-MET inhibitor can slow or shrink advanced solid tumors that have specific c-MET genetic changes. You may be eligible if your cancer has progressed after standard treatment and you meet safety and heart/health requirements.
This trial tests a drug called AMB-05X for people with colorectal cancer who have completed all intended treatments and show no signs of cancer on scans, but still have cancer DNA (ctDNA) in their blood. The goal is to see if AMB-05X can eliminate this remaining cancer DNA and prevent the cancer from coming back.
This trial tests a combination of two new drugs, BND-22 and cemiplimab, for people with certain advanced solid tumors like lung, colorectal, or ovarian cancer. It aims to see if this treatment helps control the cancer and looks at specific markers in your blood and tissue.
This trial tests a new drug, EMB-01, in people with advanced left-sided colorectal cancer that has spread or cannot be removed. It may help if standard treatments have stopped working or caused side effects.
This trial tests a new drug called EMB-01 combined with standard chemotherapy to treat colorectal cancer that cannot be surgically removed or has spread to other parts of the body. The goal is to see if this combination helps slow or shrink the cancer.
This Phase 1 trial tests EMB-07, a new treatment, in people with advanced or hard-to-treat solid tumors or certain relapsed/refractory lymphomas. The goal is to find a safe dose and learn whether it can shrink tumors.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.